Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

• By Sue Sutter

Related Content

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Jul 11 2016

Extrapolated Biosimilar Indications Won't Get More Post-Marketing Requirements

Feb 15 2016

Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?

Jul 10 2016

Biosimilar Doubleheader: Amgen's Humira Competitor Pitching First To FDA

Jun 14 2016

Related Companies

Amgen, Inc.

AbbVie Inc.

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Additional Topics

Advisory Committees Biosimilars Regulation BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window